Abstract
Cefazolin is traditionally active against Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP) isolates. The Clinical and Laboratory Standards Institute (CLSI) has twice updated cefazolin susceptibility breakpoints for EKP since 2010, but its role in the definitive treatment of cefazolin-susceptible EKP bacteremia remains debated. To assess its efficacy as a definitive agent, the 8-year cohort study consisted of 941 adults with monomicrobial cefazolin-susceptible EKP bacteremia, based on the CLSI criteria issued in 2019, was retrospectively established in a medical center. Based on the definitive antimicrobial prescription, eligible patients were categorized into the cefazolin (399 patients, 42.4%) and broader-spectrum antibiotic (BSA) (542, 57.6%) groups. Initially, fewer proportions of patients with fatal comorbidities (the McCabe classification) and the critical illness (a Pitt bacteremia score ≥4) at the onset and day 3 of the bacteremia episode were found in the cefazolin group, compared to the BSA group. After propensity-score matching, no significant difference of patient proportions between the cefazolin (345 patients) and BSA (345) groups was observed, in terms of the elderly, types and severity of comorbidities, bacteremia severity at the onset and day 3, major bacteremia sources, and the 15-day and 30-day crude mortality. In early outcomes, lengths of time to defervescence, intravenous (IV) antimicrobial administration, and hospitalization were similar in the two matched groups; lower costs of IV antimicrobial administration were observed in the cefazolin group. Notably, for late outcomes, lower proportions of post-treatment infections caused by antimicrobial-resistant pathogens (ARPs) and post-treatment mortality rates were evidenced in the cefazolin group. Conclusively, cefazolin is definitively efficacious and cost-effective for adults with community-onset cefazolin-susceptible EKP bacteremia in this one-center study, compared to BSAs. However, a prospective multicenter study should be conducted for external validation with other communities.
Highlights
Cefazolin, a parenteral first-generation cephalosporin (GC) available for study in 1972, has in vitro bactericidal activity against staphylococci, streptococci, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis [1], and gives sustained antibacterial concentrations in blood after intravenous or intramuscular use [2]
Of adults with blood cultures sampled in the emergency department (ED) during the period between January 2007 and December 2014, growth in blood cultures was retrospectively screened in a database of electric chart records
Patients were excluded if they were transferred from other hospitals, were diagnosed with bloodstream infections before ED arrival, received inadequate empirical therapy, had not been hospitalized through the ED, had a fatality within 3 days after the bacteremia onset, had been infected by cefazolin non-susceptible
Summary
A parenteral first-generation cephalosporin (GC) available for study in 1972, has in vitro bactericidal activity against staphylococci, streptococci, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis [1], and gives sustained antibacterial concentrations in blood after intravenous or intramuscular use [2]. Numerous investigations have only studied its efficacy in surgical prophylaxis [3]. Varied community-acquired Gram-positive infections, such as skin and soft-tissue infections [4], bone and joint infections [5], and continuous ambulatory peritoneal dialysis infections [6]. The CLSI has twice updated cefazolin susceptibility breakpoints for EKP isolates since 2010 [7,8], a clinical report of the therapeutic role of definitive cefazolin evidenced for bloodstream infections is lacking. Within the scope of community-onset bacteremia caused by cefazolin-susceptible. EKP isolates, based on the contemporary susceptibility standard, we compared efficacies of definitive cefazolin treatment with other definitive agents that have a broader spectrum
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
